EUVIMED · CrossrefZeitschrift
Journal of Thoracic Oncology
ISSN 1556-0864 · Elsevier BV
Neueste Artikel
The Prognostic Impact of Common Molecular Alterations in Resected Lung Adenocarcinoma and Implications for the Tenth Edition TNM Classification
Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-Year Results From Phase 3 EMPOWER-Lung 3 Part 2 Trial
Adaptive Feedback Signaling Through the FAK/SRC Pathway Promotes KRAS G12C Inhibitor Resistance
Amivantamab Induces Immune-Mediated Cytotoxicity in Mesothelioma Through EGFR and MET Engagement
Brief Report: Aumolertinib as a Switch Therapy in Osimertinib-Intolerant NSCLC—The ACTIVE Trial
Ending Tobacco Use Without Redistributing Tobacco Harm
Cytisine for Smoking Cessation Within a Lung Cancer Screening Program: Results From the Italian RISP Trial
Genomic Landscape and Clinical Impact of MTAP Loss in Driver-Positive NSCLC: Insights From a Large-Scale Real-World Chinese Cohort
Weight Gain on Lorlatinib Is Associated With Accumulation of Visceral Adipose Tissue
Phase III Study of Niraparib Plus Pembrolizumab as Maintenance Therapy for Advanced or Metastatic NSCLC (ZEAL-1L)
Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in NSCLC
Refining the Prognostic Meaning of MTAP Loss in Driver-Positive NSCLC
Central Adiposity, Confounding Medications, and the Reinterpretation of the “Obesity Paradox” in Lung Cancer Risk
Clinical Responses to Tarlatamab Among Patients With Pulmonary Carcinoid
A Three-Month Washout Is a Risk Marker, Not a Safety Threshold, Before Adjuvant Osimertinib
A Response to the Letter to the Editor: “Refining the Prognostic Meaning of MTAP Loss in Driver-Positive NSCLC”
The Weight of Success: Managing Visceral Adiposity in the Lorlatinib Era
Deeper, Broader, or Smarter? The Race for the Best Minimal Residual Disease Assay Remains Wide Open
Is Homozygous Methylthioadenosine Phosphorylase Deletion (MTAP−/−) in NSCLC an Important, Actionable, Adverse Prognostic Factor in Both Non-AGA+ and AGA+ NSCLC
Response to the Letter
Finding Synergy Without Sacrificing Safety: Novel Combination Therapies in NSCLC
A Response to the Letter to the Editor: “Central Adiposity, Confounding Medications, and the Reinterpretation of the “Obesity Paradox” in Lung Cancer Risk”
Cytisine for Smoking Cessation in Lung Cancer Screening Participants: Promise, Caveats, and a Path Forward
In This Issue
Tobacco News Update - From the IASLC Tobacco Control Committee
Tarlatamab in Pulmonary Carcinoid: A Signal Worth Chasing, Carefully
The Price of Progress in Lung Cancer: Global Disparities, Drug Costs, and the Challenge of Equitable Access
Corrigendum to ‘PP01.24: Real-World Safety and Outcomes of Tarlatamab in Extensive-Stage Small Cell Lung Cancer’ [Journal of Thoracic Oncology Volume 21 Issue 7 Supplement 1 (2026) 104022]
Smoking and Cessation Across the Continuum of Cancer Care: 20 Years of Progress Toward Cessation as Standard Cancer Treatment
Brief Report: Patterns of Disease Progression with Durvalumab versus Placebo After Concurrent Chemoradiotherapy for Limited-Stage SCLC in the Phase 3 ADRIATIC Trial
EUVIMED